Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an
about
Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?Dose-Dense Chemotherapy in Metastatic Breast Cancer: Shortening the Time Interval for a Better Therapeutic IndexA Review of Systemic Treatment in Metastatic Triple-Negative Breast CancerEribulin in the Management of Advanced Breast Cancer: Implications of Current Research FindingsHuman epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic optionsThe role of taxanes in triple-negative breast cancer: literature reviewOvarian cancer standard of care: are there real alternatives?HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneityChemotherapy-induced peripheral neurotoxicity: a critical analysisABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatmentEribulin for the treatment of metastatic breast cancer: an update on its safety and efficacyStrategies for modern biomarker and drug development in oncology.Real-world data in the molecular era-finding the reality in the real world.A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial.Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines--a phase II multipractice studyA study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles.A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).Survival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer.Peptide probes derived from pertuzumab by molecular dynamics modeling for HER2 positive tumor imaging.Critically short telomeres and toxicity of chemotherapy in early breast cancerFive-year survival of metastatic pancreatic carcinoma: a study of courage and hopeRecurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life.Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.Paclitaxel and trastuzumab for breast cancer.Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials.Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trialPeripheral neuropathy caused by Paclitaxel and docetaxel: an evaluation and comparison of symptomsHER-2 overexpression and survival in colorectal cancer: a meta-analysisChemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience.A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid CancerNanoparticle albumin-bound-Paclitaxel in the treatment of metastatic urethral adenocarcinoma: the significance of molecular profiling and targeted therapy.Recent studies that influence the chemotherapeutic paradigm in the management of advanced ovarian cancerImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116Dose-dense epirubicin and cyclophosphamide followed by weekly Paclitaxel in node-positive breast cancerOverview of neuropathy associated with taxanes for the treatment of metastatic breast cancer.Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
P2860
Q26745420-798B3A37-732F-4615-B422-418A7E76D9BFQ26751245-3BA55590-C4CC-43F9-9191-14F29A6FAA57Q26752846-FB0F4A92-78B5-4C5C-957B-A7F610741659Q26774097-33C973FA-472D-48B3-80FC-9F685457C06AQ26777681-DDAD204C-040C-48DF-9CE8-D9604DF99445Q26798356-0767FB4F-6BF0-43F7-944A-0A5F9ADE7E08Q26862249-C7891C55-0CB4-4214-887D-97DB3D52665EQ27006811-2CF9AEE4-EEC5-4B87-93AB-2444B9325725Q27010318-D9943916-9690-4269-8E84-6D081E77F3AEQ27851876-6DEE6E9B-17E3-4FEB-94F1-90D3F222511AQ28073057-501322C4-54B7-4F65-AB4B-E7F571130E3DQ28088354-37B6646F-ADBE-4301-972F-9BE23D2577B8Q30590270-B95A12D2-48B2-4C2F-900B-8C15A8F48FBCQ31023009-EAD0515E-9AAA-4401-9BA7-6AA87833E0D2Q33387547-7B54FFC5-4805-4815-8AF1-6A7ABD462FA1Q33395356-8F13010B-74AC-401A-893A-A4FD80A015F1Q33401069-EC4FB730-0510-44F2-81B8-D3356D47749CQ33407139-3CCFEEAE-EFBC-42A2-9D83-A906660DCD6DQ33407574-CD49840A-6169-4108-A1D1-1409429CC536Q33418714-4247B7E4-29F8-4E72-814D-42EF9AB72370Q33516882-0FDB2426-F017-49BF-92D3-09A5E55AA1ACQ33562598-948AE8F6-52B4-43BB-ACEE-5AEA4E3B8C71Q33591567-423C36E2-9951-4C60-AF31-7CC4F6D6CCC8Q33591948-C677CDE9-E45F-4FCE-BDA0-ECE48834D3E6Q33703527-BA6CAE23-667A-4F13-B3F7-8E2B3C7B6A6FQ33738990-F4333FEE-D7EE-4FEA-838A-C19229F45D11Q33749066-2FC432FA-D2BE-4238-A779-B1CC61AA2552Q33774794-10551AB2-1A62-42A1-948D-BC44E64732FCQ33785011-5A3C451A-6856-4AA8-BC01-2F78B81F8F8DQ33821528-E9D6CBBD-6722-4D43-B03A-968A7287C934Q33886036-3329DAEA-EFB5-440C-A8CD-F1CAB4872A5EQ33979049-C85D4691-3E88-4C8D-9EE0-39A5CFEDDB89Q33984071-ADFC9E42-73F0-4748-A9E5-C0EB14E4F03AQ34043403-9F0EB863-F4AD-40B7-BB52-917557D8185FQ34119072-274EC1FA-788D-4107-8BC0-0C88CE2EFA0AQ34167568-7844DBB2-BCC2-44CC-9BEB-8DD5560E763CQ34223890-28F34A69-D40F-4C8C-8FCF-CC9F97AAE461Q34233936-2789C244-2A1C-4924-B384-893305E846B8Q34458581-3C8A1B13-7F52-4235-B673-255E48BF9545Q34468964-5D6406B3-B4A4-49F3-82AB-576685BC2371
P2860
Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an
description
article
@en
im April 2008 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2008
@uk
name
Randomized Phase III Trial of ...... rs: Final Results of Cancer an
@en
Randomized Phase III Trial of ...... rs: Final Results of Cancer an
@nl
type
label
Randomized Phase III Trial of ...... rs: Final Results of Cancer an
@en
Randomized Phase III Trial of ...... rs: Final Results of Cancer an
@nl
prefLabel
Randomized Phase III Trial of ...... rs: Final Results of Cancer an
@en
Randomized Phase III Trial of ...... rs: Final Results of Cancer an
@nl
P2093
P356
P1476
Randomized Phase III Trial of ...... rs: Final Results of Cancer an
@en
P2093
Andrew D. Seidman
Charles L. Shapiro
Clifford Hudis
Constance Cirrincione
Diana Lake
Donald Berry
Eric Winer
Grandella Gipson
Harold Burstein
Hyman Muss
P304
P356
10.1200/JCO.2007.11.6699
P407
P50
P577
2008-04-01T00:00:00Z